CNS Pharmaceuticals Announces 1-for-12 Reverse Stock Split to Streamline Capital Structure

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, has announced a significant corporate action. The company will undergo a 1-for-12 reverse stock split, effective July 22, 2025. This move will consolidate every twelve shares of the company's common stock into one share, with adjustments also made to warrants and equity awards to maintain equity value for shareholders.

The reverse stock split is a strategic decision aimed at streamlining the company's capital structure and potentially making its stock more attractive to a broader range of investors. Following the split, the company's stock will continue to trade under the symbol CNSP but will be assigned a new CUSIP number: 18978H508. Importantly, the split will uniformly affect all shareholders, with no fractional shares issued. Shareholders who would otherwise be entitled to fractional shares will receive cash payments in lieu, ensuring fairness and simplicity in the transition.

In addition to the share consolidation, the authorized share count of CNS Pharmaceuticals will be reduced to 25 million, while the par value per share will remain unchanged at $0.001. This adjustment reflects the company's ongoing efforts to optimize its financial and operational framework, positioning itself for future growth and success in the competitive biopharmaceutical industry.

For further information on this corporate action, interested parties can refer to the detailed announcement made by CNS Pharmaceuticals. This strategic initiative underscores the company's commitment to enhancing shareholder value and its dedication to advancing treatments for brain and central nervous system cancers.